成都生物医药产业
新形势 新机遇 新跨越
Biomedical Industry in Chengdu
New Strategies New Opportunities New Achievements
主讲：何礼 先生 成都市发展和改革委员会主任
By Mr.HE Li
Director of Chengdu Municipal Development and Reform Commission
一、成都生物医药发展现状及优势
Ｉ. Current situation and advantages of the development of
biomedical industry in Chengdu
成都生物医药发展现状及优势
Current situation and advantages of the development of biological medicine industry in Chengdu
 国内重要的生物医药产业基地
 An important domestic biopharmaceutical industry bases
 2005年，成都被商务部确定为国家首批医药出口基地
 Chengdu became one of the First National Medicine Export Bases approved
by the Ministry of Commerce in 2005.
 2007年，被国家发改委认定为国家生物产业基地
 National Bio-Industrial Base approved by the National Development and Reform
Commission in 2007.
 2007年，被科技部和商务部批准为国家科技兴贸出口创新基地（生物医药）
 National Export Innovation Base of Revitalizing Trade through Sci-Tech (Biological
Medicine) approved by the Ministry of Science & Technology and the Ministry of
Commerce in 2007.
 2011年，被科技部批准为国家生物医用材料及医疗器械高新技术产业化基地
 National hi-tech Industrialization Base of Biomaterial & Medical Device approved by
the Ministry of Science & Technology in 2011.
成都生物医药发展现状及优势
Current situation and advantages of the development of biological medicine industry in Chengdu
 成都市医药工业2005-2012年主要经济指标
单位：亿元
 The Main Economic Indicators of Chengdu Medical Industry from 2001 to 2012
成都生物医药发展现状及优势
Current situation and advantages of the development of biological medicine industry in Chengdu
 产业发展基础雄厚 Solid industrial development foundation
聚集了现代中药、化学药、生物制药、药品包装材料和医药研发服务等企业近400家,
其中年主营业务收入在2000万元以上的企业202家，工业总产值居西部第一 。2012
年全市规模以上生物医药制造业实现销售收入 313.81亿元，增加值130.35亿元；医
药商贸业实现销售收入337.7亿元。
Nearly 400 enterprises gathered here, including modern TCM, chemical drugs, bio-
pharmaceuticals, medicine packing material and medical R & D services, etc, amongst
them, there are 202 enterprises , each of which owns main business revenue amount to
more than 20 million yuan per year, with a first-ranked gross value of industrial output in
west. In 2012, the total sales income of Chengdu’s bio-pharmaceutical producers above
designated size (i.e. all state-owned enterprises and those non-state-owned enterprises
with an annual sales income over 5 million yuan） has exceeded 31.381 billion yuan,
increased by 13.035 billion yuan, and the trading of medicines has exceeded 33.77
billion yuan.
成都生物医药发展现状及优势
Current situation and advantages of the development of biological medicine industry in Chengdu
 产业发展基础雄厚 Solid industrial development foundation
成都大输液产品、血液制品均已占国内市场1/3的份额
Both large infusion products and blood products in Chengdu occupy one-third of its domestic market
share.
心血康、人血白蛋白、抗病毒颗粒等39个单品种过亿元的优势产品
The sales of about 20 kinds of hit products reach over 100 million yuan , such as, Xinxuekang, Human
Serum Albumin (HSA), and Antivirus Granule, etc.
地奥集团、科伦集团、恩威集团、康弘药业等进入全国医药工业企业100强
Diao Group, Koren Group, Enwei Group and Kanghong Pharmaceutical have entered the list of Top 100
National Pharmaceutical Industrial Enterprises.
90家医药生产企业年销售收入过亿元
There are 63 medical enterprises in the city with anual output value exceeding over 100 million yuan.
科伦、华神、中汇、迪康等6家医药企业成功上市（IPO）
5 pharmaceutical enterprises, including Kelun, Huashen, Zhonghui, Dikang etc., are listed successfully
(IPO)
成都生物医药发展现状及优势
Current situation and advantages of the development of biological medicine industry in Chengdu
 自然资源丰富 Abundant natural resources
“中药之库”—总蕴藏量全国第一，药材种植和采收加工(GAP和SOP)全国领先
“ TCM Depository” —ranks first in China in the total reserves, advanced in planting,
collecting and processing medicinal materials (GAP & SOP) nationwide.
约 5000种
about 5,000 kinds
42%
药材品种占全国比重
约45万亩
Proportion of Medicinal Species in China
about 300km2
10.7%
药材种植面积占全国比重
Proportion of Planting Area in China
约42万吨
about 420,000 t
10%
药材产量占全国比重
Output Proportion in China
成都生物医药发展现状及优势
Current situation and advantages of the development of biological medicine industry in Chengdu
 自然资源丰富 Abundant natural resources
 成都拥有珍稀的猕猴资源, 建有平安猴场,可年供
2000多只优质的实验用猕猴
 Chengdu owns rare rhesus resources, and Ping’an
Monkey Breeding Center is built to provide over 2,000 topquality rhesus per year for clinic practice.
 投资1.2亿，占地170亩的四川大学华西医院实验
猕猴养研一体化产业基地启动建设
 The construction of the Rhesus Raise and Research
Base of Sichuan University West China Hospital, with a
planned investment of RMB 120 million and covering an
area of 170 mu, is officially launched.
 大量的患者群和疾病谱，让临床采样便捷
 A large number of patient groups and broad disease
spectrum facilitate clinical sampling.
成都生物医药发展现状及优势
Current situation and advantages of the development of biological medicine industry in Chengdu
 研发创新能力较强 Strong research and innovation capability
国家天然药物工程技术研究中心
National Engineering Technology Research Center for Natural Medicines
中药饮片炮制国家地方联合工程研究中心
Chinese Herbal Medicine Processing Joint Engineering Research Center
生物治疗国家重点实验室
State Key Laboratory of Biotherapy
国家手性药物工程研究中心
National Engineering Research Center of Chiral Drugs
国家生物医学材料工程技术研究中心
National Biomedical Materials Engineering Research Center
靶向药物及释药系统教育部重点实验室
Key Laboratory of Ministry of Education on Drug Targeting and Drug Delivery System
成都生物医药发展现状及优势
Current situation and advantages of the development of biological medicine industry in Chengdu
国家大容量注射制剂工程技术研究中心
National large volume injection Preparation Engineering Technology Research Center
四川大学华西医院国家药物临床试验基地
National Drug Clinical Trial Base of West China Hospital of Sichuan University
国家医用植入器械工程和检验评价中心
National Evaluation Center of Medical Implants Engineering and Testing
国家（成都）中药安全性评价中心
National (Chengdu) TCM Safety Evaluation Center
四川省疫苗工程技术研究中心
Sichuan Vaccine Research Center
四川省脐血干细胞中心
Sichuan Umbilical Cord Blood Stem Cell Center
中药资源系统研究与开发利用省部共建重点实验室
Key Laboratory of TCM Resource System Research and Exploitation
成都生物医药发展现状及优势
Current situation and advantages of the development of biological medicine industry in Chengdu
 研发创新能力较强 Strong research and innovation capability
华西生物医药公共服务平台
Biomedical Public Service Platform of West China Hospital
创新研究平台
Innovation Research Platform
药效学研究技术平台
Pharmacodynamics Research Platform
生物样品分析测试中心
Analysis and Testing Center of Biological Samples
新药安全性评价中心
New Drug Safety Evaluation Center / GLP Center
新药临床试验机构
New Drug Clinical Trial Institution / GCP Center
临床试验检测中心
Laboratory of Clinical Trial Testing Center(CAP)
四川大学华西医院现有编制床位1235张，实际开放床位5000余张，是世界规模最大的医院
West China Hospital of Sichuan University，one of the largest hospitals in the world
with 1,235 existing established beds, however, the actual number of the available
beds reaches more than 3,300.
成都生物医药发展现状及优势
Current situation and advantages of the development of biological medicine industry in Chengdu
 研发创新能力较强 Strong research and innovation capability
拥有天府生命科技园、天河孵化器等专业生物医药孵化器及一批新药研发公共服
务平台和专业服务外包机构
Chengdu has professional biomedical incubators such as Tianfu Life Science and
Technology Park, Tianhe Incubator and a batch of public service platforms and
professional service outsourcing organizations for research and development of new drugs.
已形成药物发现、临床前研究、临床试验、成果孵化及工业化生产全过程的研发
和服务体系，技术水平整体处于全国一流
Chengdu has built a research & development and service system for the whole process of
drug discovery, preclinical study, clinical trial, scientific result incubation and industrial
production，and has national first-class overall technology。
二、发展重点
Ⅲ. Development priorities
发展重点
Development priorities
Biopharmaceutical field
生物制药
Modern
TCM
Biomaterial
and Medical
Equipments
现代中药
生物医学材
料及医疗器
械
生物医药
外包服务
化学药
保健食品及
化妆品
Medical
Outsourcing
Service
Health Foods
and cosmetics
Chemical Drugs

加快生物医药产业发展，建立以生物制药为重点、化学原料制药为基础、地道
药材为特色的产业体系。

Development of medical industry will be accelerated to set up an industry
system taking biological pharmacy as key point, chemical raw material pharmacy as
basis and authentic medicinal material as feature.
发展重点
Development priorities
生物制药领域：生物技术药物、疫苗、血液制品等
Bio-pharmaceuticals: Antibodies medicines, vaccines, and recombinant viral
vectors, blood products etc.
生物医学材料及医疗器械领域：生物医学材料制品及植入器械、生物医用材料及高
端医用耗材、诊断试剂及产品、高新技术诊疗设备及系统
Biomedicines and Medical Equipments: Bioactive artificial bone materials, dental
implants, Biomedical materials and High-end medical supplies, diagnostic
reagents and products, Hi-tech diagnostic equipments (MRI medical)& system.
化学药领域：特色原料药及制剂、化学合成创新药物
Chemical Medicines: Featured API preparation and Chemical synthesis
innovative pharmaceuticals etc.
发展重点
Development priorities
现代中药领域：重大中药新药创制、中药大品种二次开发和国际化、道地药材精深加工
Modern TCM: Secondary development of large varieties of TCM, innovative
Chinese patent drugs etc.
保健食品领域：天然保健食品、营养补充类保健品
Health Foods: Natural health foods, Nutritional Supplements Health Products
生物医药外包服务领域：CRO、CMO、检验检测服务、生物治疗服务
Biomedicine Outsourcing Service: CRO, CMO, analysis and testing
Service and biological treatment service
WELCOME TO CHENGDU